New Drug-Radiation combo shows promise for Tough-to-Treat head and neck cancer
NCT ID NCT04533750
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 45 times
Summary
This early-phase trial is testing whether adding the drug peposertib to standard radiation therapy is safe and effective for people with advanced head and neck cancer who cannot take the chemotherapy drug cisplatin. The study involves 21 participants and aims to find the best dose of peposertib while monitoring side effects and tumor response. If successful, it could offer a new treatment path for this group of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Banner University Medical Center - Tucson
Tucson, Arizona, 85719, United States
-
Carle Cancer Center
Urbana, Illinois, 61801, United States
-
Carle Physician Group-Effingham
Effingham, Illinois, 62401, United States
-
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938, United States
-
Carle at The Riverfront
Danville, Illinois, 61832, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Highland Hospital
Rochester, New York, 14620, United States
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
NYU Langone Hospital - Long Island
Mineola, New York, 11501, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota, 57104, United States
-
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, 57117-5134, United States
-
Stanford Cancer Institute Palo Alto
Palo Alto, California, 94304, United States
-
The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky, 40202, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Arizona Cancer Center-North Campus
Tucson, Arizona, 85719, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Rochester
Rochester, New York, 14642, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
peposertib (a drug that may block enzymes needed for cancer cell growth)
What this could lead to
If it works, this could point toward a new treatment option for head and neck cancer patients who cannot take standard chemotherapy.
What could go wrong
This is a very early phase I trial with only 21 participants, so it is primarily testing safety and dosing. It may not show strong anti-cancer effects, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.